• Depot
  • Watchlist
  • Glocke
  • Handeln

    • EyePoint Pharmaceuticals News

    16,75 $ +3,65% +0,59 $
    In : 15,665 € | 26.04.24 22:15:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2QJRU
    ISIN: US30233G2093
    US-Symbol: EYPT
    Typ: Aktie

    EyePoint Pharmaceuticals News

    07.12.23 - PR Newswire
    Thinking about buying stock in Realty Income, Eyepoint Pharmaceuticals, Altisource Asset Management, Reviva Pharmaceuticals, or Wave Life Sciences?
    Thinking about buying stock in Realty Income, Eyepoint Pharmaceuticals, Altisource Asset Management, Reviva Pharmaceuticals, or Wave Life Sciences? PR Newswire
    06.11.23 - wallstreet:online Zentralredaktion
    November-Top-Aktien von Mizuho: Coterra, Merck und andere: Mit 300 Prozent Kurspotenzial sticht eine hervor!
    Das Research-​Team von Mizuho hat seine neuen Aktientipps für den November preisgegeben.Nach der Kursflaute im Oktober befinden sich die großen Aktienindizes wie der Dow ...
    03.05.23 - PR Newswire
    Thinking about buying stock in ImmunoGen, Mersana Therapeutics, Unisys, Eyepoint Pharmaceuticals, or BioCryst Pharmaceuticals?
    Thinking about buying stock in ImmunoGen, Mersana Therapeutics, Unisys, Eyepoint Pharmaceuticals, or BioCryst Pharmaceuticals? PR Newswire
    28.01.23 - PR Newswire
    EYEPOINT SHAREHOLDER ACTION REMINDER
    EYEPOINT SHAREHOLDER ACTION REMINDER PR Newswire
    22.01.23 - PR Newswire
    EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options
    EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him ...
    15.01.23 - PR Newswire
    EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options
    EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him ...
    01.01.23 - PR Newswire
    EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options
    EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him ...
    25.12.22 - PR Newswire
    EYEPOINT INVESTOR ALERT
    EYEPOINT INVESTOR ALERT PR Newswire
    18.12.22 - PR Newswire
    EYEPOINT INVESTOR ALERT
    EYEPOINT INVESTOR ALERT PR Newswire
    01.08.22 - PR Newswire
    EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD
    EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD PR Newswire
    15.07.22 - PR Newswire
    EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
    EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD PR Newswire
    12.02.22 - PR Newswire
    EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
    EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet ...
    17.11.21 - PR Newswire
    Thinking about buying stock in Purecycle Technologies, Innoviz Technologies, CNS Pharmaceuticals, Uphealth, or Eyepoint Pharmaceuticals?
    Thinking about buying stock in Purecycle Technologies, Innoviz Technologies, CNS Pharmaceuticals, Uphealth, or Eyepoint Pharmaceuticals? PR Newswire
    13.11.21 - PR Newswire
    EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
    EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD - Interim six-month ...
    27.09.19 - The Motley Fool
    3 Top-Biotech-Aktien für September
    Biotech-​Aktien entwickeln sich in den Sommermonaten nur selten gut, und 2019 war da keine Ausnahme. So ist beispielsweise der iShares Nasdaq Biotechnology ETF seit dem ...
    13.12.10 - Aktiencheck
    pSivida FDA-Entscheidung zu Iluvien erwartet - Der Aktionär
    Nach Einschätzung der Experten vom Anlegermagazin "Der Aktionär" weist die pSivida-​Aktie ein ausgeglichenes Chance/Risiko-​Verhältnis auf. Die US-​Gesundheitsbehörde FDA ...
    28.12.09 - Der Aktionär
    Psivida: Kurssprung nach Phase-III-Daten

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »